Sun Pharmaceutical Industries (SUNPHARMA.NS) Stock Price
Sun Pharmaceutical Industries Price
Over the last 19 years Sun Pharmaceutical Industries grew revenue by 19.0% annually, reaching 582.20 B INR. Earnings per share have grown at 14.1% per year over the last 19 years. For Sun Pharmaceutical Industries, the net margin of 19.7% is up versus 8.5% a few years ago. At today's price the dividend yield works out to roughly 0.93%. The payout ratio is around 34% of earnings. The dividend has grown at 18.3% per year over the past 19 years. The consensus 12-month price target for Sun Pharmaceutical Industries is 2,016.03 INR, about 13.9% above where the stock trades today. Of 40 analysts, 34 rate the stock a buy — an overall Buy consensus.
Sun Pharmaceutical Industries stock price
Sun Pharmaceutical Industries business model & stock analysis
Frequently asked questions about Sun Pharmaceutical Industries
The business model of Sun Pharmaceutical Industries Ltd is focused on manufacturing and distributing pharmaceutical products across the globe. As one of the largest pharmaceutical companies in India, Sun Pharma operates through various divisions including formulations, active pharmaceutical ingredients (APIs), and research and development. With a strong emphasis on product quality and innovation, Sun Pharma aims to improve healthcare accessibility by providing high-quality and affordable medications to patients worldwide. The company’s wide portfolio encompasses a diverse range of therapeutic areas such as cardiology, psychiatry, neurology, and more. Sun Pharmaceutical Industries Ltd strives to constantly evolve and grow, serving the healthcare industry with integrity and excellence.
Sun Pharmaceutical Industries Ltd is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Sun Pharmaceutical Industries Ltd in the market include Cipla Ltd, Lupin Ltd, Dr. Reddy's Laboratories Ltd, and Aurobindo Pharma Ltd.
Sun Pharmaceutical Industries Ltd, founded in 1983, is a renowned Indian multinational pharmaceutical company. With its headquarters in Mumbai, the company has consistently grown and developed a strong presence in the global pharmaceutical market. Sun Pharma has a rich history of delivering high-quality and affordable medications across a wide range of therapeutic areas. Their focus on research and development, combined with strategic collaborations and acquisitions, has propelled them to become a leading player in the industry. Sun Pharmaceutical Industries Ltd has significantly contributed to improving global healthcare and continues to be a trusted name in the pharmaceutical sector.
Sun Pharmaceutical Industries Ltd has achieved several significant milestones throughout its history. Notably, the company became the largest pharmaceutical company in India and one of the top generic companies globally. Sun Pharma successfully acquired Taro Pharmaceutical Industries, a US-based company, which significantly expanded its presence in the international market. Moreover, the acquisition of Ranbaxy Laboratories positioned Sun Pharma as the largest pharmaceutical company in India and the fifth-largest globally. Sun Pharma has also received numerous accolades and awards for its research and development efforts, innovation, and manufacturing excellence. These milestones highlight Sun Pharmaceutical Industries Ltd's continuous growth and success in the pharmaceutical industry.
Sun Pharmaceutical Industries Ltd is primarily present in several countries and regions around the world. The company has a strong presence in India, where it is headquartered, and it has also expanded its operations globally. Sun Pharma has a significant presence in the United States, making it one of the leading generic pharmaceutical companies in the country. Additionally, the company has a strong market presence in emerging markets such as Russia, Brazil, South Africa, and several countries in Europe. With its global footprint, Sun Pharmaceutical Industries Ltd continues to establish itself as a prominent player in the international pharmaceutical industry.
Sun Pharmaceutical Industries Ltd represents core values of integrity, innovation, and excellence. As a leading pharmaceutical company, Sun Pharma is dedicated to providing high-quality, affordable healthcare solutions worldwide. The company prides itself on its robust corporate philosophy, focusing on ethical business practices, patient-centricity, and continuous improvement. Sun Pharma strives to enhance access to life-saving medications and transform patients' lives through cutting-edge research and development. With a commitment to social responsibility and sustainability, Sun Pharma aims to make a positive impact on communities and create long-term value for its stakeholders.
Analysts currently set an average price target of 2,000.40 INR for the Sun Pharmaceutical Industries stock (median: 2,016.03 INR), implying +13.0 % versus the latest price. The consensus is based on 40 analyst ratings.
40 analysts currently rate the Sun Pharmaceutical Industries stock: 35 recommend buying, 1 holding and 4 selling.
Converted at the current exchange rate, the Sun Pharmaceutical Industries share trades at 16.56 EUR (1,770.70 INR).
The Sun Pharmaceutical Industries share (SUNPHARMA.NS) is listed on 2 stock exchanges, including: NSE (Indien) (SUNPHARMA.NS).
Sun Pharmaceutical Industries Ltd is an Indian multinational company that specializes in the development, manufacturing, and marketing of generic drugs and innovative products. The company operates in over 150 countries and has a portfolio of over 2000 products. The business model of Sun Pharma is divided into several divisions. Firstly, there is the generic drugs division, which specializes in the manufacturing and marketing of affordable medications. The company produces generics in various therapeutic areas such as neurology, oncology, cardiology, gastroenterology, and many others, providing effective and affordable treatment options for patients. In addition to the generic drugs division, Sun Pharma also has a comprehensive branded products division. Here, the company focuses on developing innovative therapies and marketing branded products in key areas such as dermatology, orthopedics, ophthalmology, and psychiatry. This allows Sun Pharma to leverage its competitive advantage and differentiate itself from other companies. In the research and development field, Sun Pharma collaborates closely with international partners. The company is committed to expanding its portfolio of innovative products and focuses on areas such as oncology, neurology, and dermatological therapies. An example of Sun Pharma's commitment to research and development is the introduction of Tildrakizumab, a groundbreaking product for the treatment of moderate to severe plaque psoriasis. This product was developed in partnership with Almirall SA and successfully launched in the United States and Europe. Another example of Sun Pharma's leading position in the market is products like Ilumya, a medication for the treatment of psoriasis, and Ezallor, a medication for lowering cholesterol levels. These products have been successfully introduced in the United States and have the potential to significantly increase the company's revenue in the future. Sun Pharma values quality and strictly adheres to international guidelines and standards. The company is certified by various certification bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In addition to the above-mentioned business divisions, Sun Pharma also operates a strategic investment portfolio to ensure long-term growth and stability. The company invests in promising companies that align with its business areas, demonstrating a high level of strategic foresight. Overall, the business model of Sun Pharmaceutical Industries Ltd is focused on growth. Through a variety of strategic business units and products, the company can fully leverage its global potential and expand its portfolio. The pursuit of quality and innovation is an integral part of the company's philosophy and is at the center of each business unit.
The revenue of Sun Pharmaceutical Industries is 582.20 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Sun Pharmaceutical Industries is 114.79 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Sun Pharmaceutical Industries is currently 37.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sun Pharmaceutical Industries stock.
The price-to-sales ratio (P/S) of Sun Pharmaceutical Industries is currently 7.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sun Pharmaceutical Industries stock.
The Eulerpool Quality Score for Sun Pharmaceutical Industries is 7/10.
The ISIN of Sun Pharmaceutical Industries is INE044A01036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Sun Pharmaceutical Industries is SUNPHARMA.NS. The ticker symbol is used to trade Sun Pharmaceutical Industries shares on the stock exchange.
Sun Pharmaceutical Industries stock
Sun Pharmaceutical Industries Peer Group
Sun Pharmaceutical Industries Ticker
Sun Pharmaceutical Industries FIGI
All fundamentals and in-depth analysis of Sun Pharmaceutical Industries
Our stock analysis for Sun Pharmaceutical Industries stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sun Pharmaceutical Industries. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.